Previous 10 | Next 10 |
ALPHARETTA, Ga., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management will ...
Clearside Biomedical, Inc. (CLSD) Q3 2019 Earnings Conference Call November 06, 2019, 16:30 ET Company Participants Jenny Kobin - Head, IR George Lasezkay - Interim CEO & Director Thomas Ciulla - Chief Medical Officer Charles Deignan - CFO Conference Call Participants ...
Clearside Biomedical (NASDAQ: CLSD ): Q3 GAAP EPS of -$0.17 misses by $0.01 . More news on: Clearside Biomedical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases – – Suprachoroidal Axitinib IND Submission Targeted for Mid-2020 – – Management to Host ...
ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its third q...
Gainers : Neuralstem (NASDAQ: CUR ) +69% . IVERIC (NASDAQ: ISEE ) +50% . Big 5 Sporting Goods (NASDAQ: BGFV ) +31% . Clearside Biomedical (NASDAQ: CLSD ) +23% . OneSpan (NASDAQ: OSPN ) +20% . MutualFirst Financial (NASDAQ: MFSF ) +20% . Cellect Biotechnology (NASDAQ: APOP ) +21...
ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that REGENXBIO ...
Nano cap Clearside Biomedical (NASDAQ: CLSD ) is up 21% premarket on modest volume in reaction to its exclusive license agreement with Bausch Health Companies' (NYSE: BHC ) Bausch + Lomb for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) for the pote...
Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis Canada NewsWire LAVAL, Quebec and ALPHARETTA, Ga., Oct. 23, 2019 NDA Resubmiss...
ALPHARETTA, Ga., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple or...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...